IDAMYCIN PFS Injection in combination with other approved antileukemic drugs is indicated for the treatment of acute myeloid leukemia (AML) in adults.This includes French-American-British (FAB) classifications M1 through M7.
Idarubicin is intended for administration under the supervision of a physician who is experienced in leukemia chemotherapy.Idarubicin is a potent bone marrow suppressant.
Idarubicin should not be given to patients with pre-existing bone marrow suppression induced by previous drug therapy or radiotherapy unless the benefit warrants the risk.Severe myelosuppression will occur in all patients given a therapeutic dose of this agent for induction, consolidation or maintenance.
Careful hematologic monitoring is required.
Deaths due to infection and/or bleeding have been reported during the period of severe myelosuppression.
Facilities with laboratory and supportive resources adequate to monitor drug tolerability and protect and maintain a patient compromised by drug toxicity should be available.
It must be possible to treat rapidly and completely a severe hemorrhagic condition and/or a severe infection.Pre-existing heart disease and previous therapy with anthracyclines at high cumulative doses or other potentially cardiotoxic agents are co-factors for increased risk of idarubicin-induced cardiac toxicity and the benefit to risk ratio of idarubicin therapy in such patients should be weighed before starting treatment with idarubicin.Myocardial toxicity as manifested by potentially fatal congestive heart failure, acute life-threatening arrhythmias or other cardiomyopathies may occur following therapy with idarubicin.
Appropriate therapeutic measures for the management of congestive heart failure and/or arrhythmias are indicated.Cardiac function should be carefully monitored during treatment in order to minimize the risk of cardiac toxicity of the type described for other anthracycline compounds.
The risk of such myocardial toxicity may be higher following concomitant or previous radiation to the mediastinal-pericardial area or in patients with anemia, bone marrow depression, infections, leukemic pericarditis and/or myocarditis.
While there are no reliable means for predicting congestive heart failure, cardiomyopathy induced by anthracyclines is usually associated with a decrease of the left ventricular ejection fraction (LVEF) from pretreatment baseline values.Since hepatic and/or renal function impairment can affect the disposition of idarubicin, liver and kidney function should be evaluated with conventional clinical laboratory tests (using serum bilirubin and serum creatinine as indicators) prior to and during treatment.
In a number of Phase III clinical trials, treatment was not given if bilirubin and/or creatinine serum levels exceeded 2 mg%.
However, in one Phase III trial, patients with bilirubin levels between 2.6 and 5 mg% received the anthracycline with a 50% reduction in dose.
Dose reduction of idarubicin should be considered if the bilirubin and/or creatinine levels are above the normal range.(See DOSAGE AND ADMINISTRATION.)